Health Guidance

Preclinical Models: Innovative solutions to accelerate drug discovery and development

Preclinical models are developed to test lead compounds for toxicity and efficacy. They are valuable tools to minimize development costs and reduce failures prior to commencement of human trials. Problems with traditional animal models such as cost, ethics, and suitability has prompted researchers to develop new models and systems to overcome such disadvantages. Continue reading ‘Preclinical Models – Innovative Solutions To Accelerate Drug Discovery And Development’ »

US healthcare reform: a double-edged sword

The US House of Representatives has passed legislation paving the way for major healthcare system reform designed to substantially decrease the number of individuals without health insurance. Despite its potential benefits, it believes that the reform is a mixed blessing for the pharmaceutical industry as cost-containment pressures are set to intensify in the long term. ( http://www.bharatbook.com/detail.asp?id=134206&rt=Pharmaceutical-Licensing-Overview.html )

The landmark bill will overhaul the US healthcare system, aiming to reduce the number of individuals without healthcare insurance, improve access to healthcare and curb escalating costs. The bill focuses on health insurance system reform, specifically: expanding Medicaid insurance coverage for the poor; implementing stricter rules for private health insurers; outlining the creation of an individual mandate to purchase insurance; and introducing health insurance premium subsidies. Continue reading ‘US healthcare reform: a double-edged sword’ »

Incoming search terms:

• obama\s double sided sword on health care (2)

HTML clipboard

The Kenya Pharmaceuticals and Healthcare Report

Independent 5-year pharmaceutical and healthcare industry forecasts for Kenya. Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Kenyan pharmaceutical and healthcare industry. Competitive intelligence, Kenyan pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Kenyan market. ( http://www.bharatbook.com/Market-Research-Reports/Pharmaceuticals-Healthcare-Report-Kenya.html )

The Kenya Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments. Kenya Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Kenyan pharmaceutical and healthcare industry.

Key Benefits of Report :

* Benchmark Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Kenya to test other views – a key input for successful budgeting and strategic business planning in the Kenyan pharmaceutical and healthcare market. Continue reading ‘Opportunities & Risks in the Kenyan Pharmaceutical and Healthcare Sector’ »

Incoming search terms:

• the global pharmaceutical industry swallowing a bitter pill (6)
• swot analysis the global pharmaceutical industry swallowing a bitter pill (4)
• kenya pharma market (4)
• swot analysis of health care system of kenya (4)
• pharmaceutical competitors of kenya (2)
• REGULATION OF THE PHARMACEUTICAL INDUSTRY IN KENYA (2)
• swot analysis of health care in kenya (2)
• swot analysis pharmaceutical industry in kenya (2)
• business opportunities and risks in natural skin care industry (2)
• swot analysis the global pharmaceutical industry: swallowing a bitter pill (2)
• the global pharmaceutical industry swallowing a bitter pill pestel analysis (2)
• the global pharmaceutical industry: swallowing a bitter pill PESTEL (2)
• pharmaceutical analysts in kenya (2)
• Pharma market trend in Kenya (2)
• pestel analysis the global pharmaceutical industry swallowing a bitter pill (2)

Global healthcare market is evolving from traditional healthcare system to modern healthcare system of E-health which minimizes the physical movement of patients and enhances the coverage of healthcare services. As the world population is aging, it has resulted in increase of global healthcare expenditure. The major increase in healthcare expenditure is being witnessed in developed nations where population is ageing at a higher pace compared to less developed nations. Aging population has resulted in increase in demand of healthcare services which is already in an over-pressurized state.

It is now believed that telemedicine is going to be an important component of the modern healthcare system which will ease the pressure over the existing healthcare system which is suffering from problems like lack of required number of physicians, high cost and limited reach in the rural areas. Telemedicine, being a component of E-health, is a provision of healthcare services that uses telecommunication technology and multimedia equipment to provide healthcare solutions over a geographic distance. Continue reading ‘New Report "analysis Of Telemedicine Market" Available Through Aarkstore Enterprise’ »

Pfizer’s novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug’s analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, it expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy. ( http://www.bharatbook.com/detail.asp?id=130154&rt=Stakeholder-Insight-Osteoarthritis-Drug-development-lags-behind-rising-osteoarthritis-population.html )

Pfizer has announced positive results from three Phase II trials in pain at the American Academy of Pain Medicine’s 26th Annual Meeting. The randomized, double-blind, placebo-controlled six-week trials in patients with chronic low back pain (CLBP) and interstitial cystitis receiving a single intravenous infusion of tanezumab (200mcg/kg) met their primary endpoints of significantly superior pain relief over placebo. Continue reading ‘Pfizer's novel NGF pain drug is potential game changer’ »

Incoming search terms:

• NGF pain drug (4)
• alternative ngf pathway and pain (2)
• what chronic pain conditions would ngf drugs treat (2)

Roche: novel Herceptin formulation promises greater convenience

Having stepped up lifecycle management for its leading breast cancer monoclonal antibody, Herceptin, Roche hopes to encourage uptake of a more convenient formulation of the drug. This strategy could help to conserve its share of an increasingly competitive market, but may be challenging to implement due to concerns over compliance and financial incentives to prescribe intravenous cancer drugs. ( http://www.bharatbook.com/detail.asp?id=68637&rt=F-Hoffmann-La-Roche-Ltd-PharmaVitae-Profile.html )

Roche has invested roughly CHF190m ($183m) at two production sites to manufacture devices that will allow patients to self-administer a subcutaneous formulation of Herceptin (trastuzumab; Roche/Genentech/Chugai). Continue reading ‘Roche: novel Herceptin formulation promises greater convenience’ »

Incoming search terms:

• herceptin competitors (4)
• herceptin formulation (2)
• herceptin market size (2)
• subcutaneous trastuzumab device (2)

Oncology Market Leaders – Analyses and Outlook – 2010-2025

Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows. ( http://www.bharatbook.com/detail.asp?id=132312&rt=Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025.html )

The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions. Continue reading ‘Comprehensive Analysis Of The Oncology Market Sector’ »

The report provides market landscape, competitive landscape and market trends information on four ophthalmic devices market categories – cataract surgery devices, refractive surgery devices, vision care, and ophthalmic diagnostic equipment. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.( http://www.bharatbook.com/detail.asp?id=133653&rt=The-Future-of-Ophthalmic-Devices-Market-Forecasts-and-Growth-Opportunities-to-2016-The-Vision-Care-Segment-Emerges-as-a-Key-Revenue-Generator.html )

The Global Ophthalmic Devices Market to Reach $28 billion by 2016The global ophthalmic devices market is forecast to reach $28 billion by 2016 with a Compound Annual Growth Rate (CAGR) of 2.5% from 2009-2016. The market is expected to be driven by a huge population suffering from vision problems, the availability of reimbursement for a majority of the devices and surgeries and the direct to consumer approach of the companies. The aging population is also an important growth driver for the market. The availability and accessibility of treatment for a majority of vision problems is also leading to increased patient demand and a subsequent growth in the market. This report provides key data, information and analysis on the global ophthalmic devices market.

The US to Continue to be the Biggest Ophthalmic Devices Market
The US is the biggest market for ophthalmic devices, contributing 26% towards the global market in 2009, and this contribution is expected to increase to 27% in 2016. The US ophthalmic devices market was valued at $6 billion in 2009 and is forecast to grow at a CAGR of 3.4% to reach $7.6 billion in 2016. The market is expected to be driven by the high prevalence of vision problems, the increasing contribution of employees and employers for vision care coverage and the availability and easy accessibility of the latest medical interventions for affected patients. Continue reading ‘Vision Care Market Remains The Largest Category In The Global Ophthalmic Devices Market’ »

Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth

Despite major advances in treatment in the last decade, a considerable percentage of the leukemia population still has high unmet needs. Some key oncology companies have entered the leukemias market fairly recently while others are pursuing late-phase development in this indication, hoping to exploit the commercial potential of patient subgroups underserved by existing treatment options. ( http://www.bharatbook.com/detail.asp?id=134190&rt=Pipeline-Insight-Leukemias-Underserved-patient-populations-offer-potential-for-market-growth.html ) Continue reading ‘Pipeline Insight Leukemias Underserved Patient Populations Offer Potential For Market Growth’ »

EASD 2009: Lantus defended amid allegations of increased cancer risk

It presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed. ( http://www.bharatbook.com/detail.asp?id=91847&rt=Commercial-Insight-Cardiovascular-and-Metabolic-Market-Overview-Diabetes-to-the-fore-as-generics-hit-primary-care-markets.html )

Although the European Association for the Study of Diabetes (EASD) recommended the continued use of Lantus in type 1 and type 2 diabetics, it has called for increased research into the relationship between insulin therapy – particularly Lantus (insulin glargine; Sanofi-Aventis) – and the risk of cancer.

It was postulated during the discussion at the 2009 EASD meeting that insulin use may be related to the increased incidence of cancer seen in diabetics over that seen in the general population. The preliminary data discussed in the symposium suggested lower rates of cancer with Levemir (insulin detemir; Novo Nordisk) compared to neutral protamine Hagedorn (NPH), but higher rates with Lantus. Continue reading ‘EASD 2009 – Lantus defended amid allegations of increased cancer risk’ »